Wednesday, June 3, 2020

Evofem Looks To Raise $100M In Additional Public Offering

San Diego-based Evofem Biosciences, a publicly held, biopharmaceuticals company which is developing products in the area of women's sexual and reproductive health, says it has priced approximately $100M in common stock to the public. The company said gross proceeds from the offering to Evofem, before deducting the underwriting discounts and commissions an

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.